Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Open-label Extension Study in Prostate Cancer
NCT02960022Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Dec 2016
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 2, open-label trial of enzalutamide in prostate cancer (PCa) and breast cancer (3 arms), sponsored by Astellas Pharma. Primary endpoint: Number of participants with adverse events at 96 months. Started Dec 2016; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)breast cancer
Beyond the preview
Go deeper on NCT02960022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960022.